Document is current
Any future updates will be listed below
-
Authors
Luostarinen, Annu
Vuorela, Arja
Kerkelä, Erja
Patrikoski, Mimmi
Kotovuori, Annika
Koski, Jan
Ahoniemi, Jonna
Lähteenmäki, Kaarina
Lehtisalo, Jenni
Oja, Terhi
Paavilainen, Henrik
Autio, Anu
Nyman, Marie
Nikoskelainen, Veera
Kergourlay, Virginie
Elbasani, Endrit
van Veen, Bert
Thotakura, Anil
Monzo, Hector
Ojala, Päivi M.
Korhonen, Matti
Hongisto, Heidi
Laitinen, Anita
-
Funding
Funding for this research was provided by:
Orion Pharma, Finland
- License Information
-
More Information
Article History
Received: 11 October 2024
Accepted: 3 March 2025
First Online: 8 March 2025
Declarations
:
: J.L., T.O., H.P., A.A., V.N., M.N., E.E., V.K., B.V., and A.T. were employed by Orion Pharma during this project. A.A. is a current employee of MSD Finland. P.M.O. and H.M. have performed CRO work for Orion Pharma in the development of FiCAR-based CAR T-cell therapies. M.K. and J.K. are inventors of a CAR structure-related patent application. The remaining authors have no commercial, proprietary, or financial interest in the products or companies described in this article.
